Michael J. Pinkoski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael J. Pinkoski has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Douglas R. Green
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, USA
5 shared publications - Nathalie Droin
INSERM U1287, Gustave Roussy Cancer Center, Villejuif, France
2 shared publications Katja C Zimmermann
Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
1 shared publicationLaurent Genestier
Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121; ‡Institut National de la Santé et de la Recherche Médicale U404, Tour Centre d'Etudes et de Recherches en Virologie et Immunologie, 21 Avenue Tony Garnier, 69365 Lyon Cedex 03 France; and§ Department of Ophthalmology, Washington University, St. Louis, MO 63110
1 shared publicationTesu Lin
Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121; ‡Institut National de la Santé et de la Recherche Médicale U404, Tour Centre d'Etudes et de Recherches en Virologie et Immunologie, 21 Avenue Tony Garnier, 69365 Lyon Cedex 03 France; and§ Department of Ophthalmology, Washington University, St. Louis, MO 63110
1 shared publicationThomas A. Ferguson
Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121; ‡Institut National de la Santé et de la Recherche Médicale U404, Tour Centre d'Etudes et de Recherches en Virologie et Immunologie, 21 Avenue Tony Garnier, 69365 Lyon Cedex 03 France; and§ Department of Ophthalmology, Washington University, St. Louis, MO 63110
1 shared publication
Latest Publications
- 1 February 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (2) , 106-108
Granzyme A: the road less traveled
- 1 February 2003
- Published by Springer Nature in Nature Immunology
- Vol. 4 (2) , 106-108
Granzyme A: the road less traveled
- 26 November 2002
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (25) , 16174-16179
Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion
Peripheral lymphocyte deletion is required for reduction of lymphocyte numbers after expansion in response to antigen. Peripheral deletion is mediated in part by the activation of apoptosis by engagement of the death receptor, Fas (CD95), by its ligand, Fas ligand (FasL; CD95L), among other mechanisms. Here we used T cell receptor (TCR) transgenic animals to examine the role of inducible expression of nonlymphoid FasL in response to peptide antigen. Antigenic challenge of TCR transgenic mice resulted in increased expression of FasL in a number of nonlymphoid tissues including the epithelium of the small intestine. Similar results were obtained in an adoptive transfer system in which TCR transgenic T cells were transferred into recipient animals. The functional relevance of nonlymphoid FasL in peripheral deletion is supported by the observation that FasL-deficientgldanimals showed a significantly reduced rate of clearance of transferred antigen-specific lymphocytes, although the lymphocytes themselves were wild type for FasL. These observations were supported further by studies in a transgenic mouse model wherelacZwas expressed under the control of the proximal promoter of theFasLgene. Using these transgenic mice, we observed induced activity of theFasLpromoter in intestinal epithelial cells throughout the crypts and villi, where we also observed infiltration of activated T cells. These data demonstrate that nonlymphoid FasL is expressed in response to peripheral T cell activation and participates in the regulation of T cells that infiltrate peripheral tissues.
- 26 November 2002
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (25) , 16174-16179
Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion
Peripheral lymphocyte deletion is required for reduction of lymphocyte numbers after expansion in response to antigen. Peripheral deletion is mediated in part by the activation of apoptosis by engagement of the death receptor, Fas (CD95), by its ligand, Fas ligand (FasL; CD95L), among other mechanisms. Here we used T cell receptor (TCR) transgenic animals to examine the role of inducible expression of nonlymphoid FasL in response to peptide antigen. Antigenic challenge of TCR transgenic mice resulted in increased expression of FasL in a number of nonlymphoid tissues including the epithelium of the small intestine. Similar results were obtained in an adoptive transfer system in which TCR transgenic T cells were transferred into recipient animals. The functional relevance of nonlymphoid FasL in peripheral deletion is supported by the observation that FasL-deficientgldanimals showed a significantly reduced rate of clearance of transferred antigen-specific lymphocytes, although the lymphocytes themselves were wild type for FasL. These observations were supported further by studies in a transgenic mouse model wherelacZwas expressed under the control of the proximal promoter of theFasLgene. Using these transgenic mice, we observed induced activity of theFasLpromoter in intestinal epithelial cells throughout the crypts and villi, where we also observed infiltration of activated T cells. These data demonstrate that nonlymphoid FasL is expressed in response to peripheral T cell activation and participates in the regulation of T cells that infiltrate peripheral tissues.
- Open Access
- 1 November 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (44) , 42380-42385
Tumor Necrosis Factor α Up-regulates Non-lymphoid Fas-ligand following Superantigen-induced Peripheral Lymphocyte Activation
- 1 November 2002
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (44) , 42380-42385
Open AccessTumor Necrosis Factor α Up-regulates Non-lymphoid Fas-ligand following Superantigen-induced Peripheral Lymphocyte Activation
- 1 January 2002
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (1) , 43-49
Lymphocyte apoptosis: refining the paths to perdition
Significant advances have been made in the study of mechanisms by which apoptosis regulates immune function. One area receiving renewed attention is killing of target cells by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. A new perspective suggests that granzyme B enters cells via receptor-mediated endocytsosis, after which it can act via mitochondrial disruption to trigger apoptotic pathways. The study of intracellular mechanisms driving lymphocyte death also saw major advances as the Bcl-2 family of proteins continues to grow in number and complexity. In addition, the intricacies of the mitochondrial role in apoptosis are starting to unravel with reports of novel proteins, such as Smac/DIABLO, and old proteins, such as heat shock proteins, playing new roles in regulating cell death.
- 1 January 2002
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 9 (1) , 43-49
Lymphocyte apoptosis: refining the paths to perdition
Significant advances have been made in the study of mechanisms by which apoptosis regulates immune function. One area receiving renewed attention is killing of target cells by cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. A new perspective suggests that granzyme B enters cells via receptor-mediated endocytsosis, after which it can act via mitochondrial disruption to trigger apoptotic pathways. The study of intracellular mechanisms driving lymphocyte death also saw major advances as the Bcl-2 family of proteins continues to grow in number and complexity. In addition, the intricacies of the mitochondrial role in apoptosis are starting to unravel with reports of novel proteins, such as Smac/DIABLO, and old proteins, such as heat shock proteins, playing new roles in regulating cell death.
- 1 May 2001
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 7 (5) , 195-197
In the company of killers
- 1 May 2001
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 7 (5) , 195-197
In the company of killers
- 1 February 2000
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 10 (1) , 114-119
Cloak and dagger in the avoidance of immune surveillance
- 1 February 2000
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 10 (1) , 114-119
Cloak and dagger in the avoidance of immune surveillance